PT2432766E - Composto anti-canceroso e composição farmacêutica que o contém - Google Patents

Composto anti-canceroso e composição farmacêutica que o contém

Info

Publication number: PT2432766E
Authority: PT; Portugal
Prior art keywords: compound; same; pharmaceutical composition; composition containing; anticancer compound
Prior art date: 2009-05-18

Application number

PT107287682T

Other languages

English (en)

Inventor

Jean-Christophe Carry

Michel Cheve

Francois Clerc

Cecile Combeau

Sylvie Gontier

Alain Krick

Sylvette Lachaud

Laurent Schio

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-18

Filing date

2010-05-17

Publication date

2013-10-23

2010-05-17 Application filed by Sanofi Sa filed Critical Sanofi Sa

2013-10-23 Publication of PT2432766E publication Critical patent/PT2432766E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PT107287682T 2009-05-18 2010-05-17 Composto anti-canceroso e composição farmacêutica que o contém PT2432766E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0902392A FR2945535B1 (fr)	2009-05-18	2009-05-18	Compose anticancereux et composition pharmaceutique le contenant

Publications (1)

Publication Number	Publication Date
PT2432766E true PT2432766E (pt)	2013-10-23

Family

ID=40973187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT107287682T PT2432766E (pt)	2009-05-18	2010-05-17	Composto anti-canceroso e composição farmacêutica que o contém

Country Status (34)

Country	Link
US (2)	US9073917B2 (pt)
EP (1)	EP2432766B1 (pt)
JP (1)	JP5656981B2 (pt)
KR (1)	KR20120032483A (pt)
CN (1)	CN102459193B (pt)
AR (1)	AR076686A1 (pt)
AU (1)	AU2010251013B2 (pt)
BR (1)	BRPI1012201A2 (pt)
CA (1)	CA2762233C (pt)
CL (1)	CL2011002930A1 (pt)
CO (1)	CO6400138A2 (pt)
CY (1)	CY1114850T1 (pt)
DK (1)	DK2432766T3 (pt)
EA (1)	EA021084B1 (pt)
ES (1)	ES2430989T3 (pt)
FR (1)	FR2945535B1 (pt)
HR (1)	HRP20130959T1 (pt)
IL (1)	IL216361A0 (pt)
JO (1)	JO2852B1 (pt)
MA (1)	MA33356B1 (pt)
ME (1)	ME01542B (pt)
MX (1)	MX2011012356A (pt)
MY (1)	MY152995A (pt)
NZ (1)	NZ596464A (pt)
PL (1)	PL2432766T3 (pt)
PT (1)	PT2432766E (pt)
RS (1)	RS53002B (pt)
SG (1)	SG176169A1 (pt)
SI (1)	SI2432766T1 (pt)
SM (1)	SMT201400005B (pt)
TW (1)	TWI441822B (pt)
UY (1)	UY32644A (pt)
WO (1)	WO2010133794A1 (pt)
ZA (1)	ZA201108447B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2945535B1 (fr)	2009-05-18	2011-06-10	Sanofi Aventis	Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) *	2010-11-17	2012-05-18	Sanofi Aventis	Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
JP6321662B2 (ja)	2012-10-12	2018-05-09	ザブロードインスティテュート, インコーポレーテッドThe Broad Institute, Inc.	Ｇｓｋ３阻害剤およびその使用の方法
MX2016016870A (es)	2014-07-01	2017-05-01	Takeda Pharmaceuticals Co	Compuestos heterociclicos y su uso como inhibidores de receptor huerfano relacionado con retinoide (ror) gamma-t.
US11203601B2 (en)	2017-04-05	2021-12-21	The Broad Institute, Inc.	Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof
JP2024519306A (ja)	2021-05-12	2024-05-10	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ｃＧＡＳ阻害薬としてのＮ結合環状置換基を有するピリジン誘導体
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
WO2025034702A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh)	2023-10-12	2025-08-01	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025233174A1 (en) *	2024-05-08	2025-11-13	Boehringer Ingelheim International Gmbh	Benzimidazole derivatives as cgas inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1242422A1 (en)	1999-11-19	2002-09-25	Abbott Laboratories	Tricyclic dihydropyrimidine potassium channel openers
CN1630656A (zh)	2001-02-02	2005-06-22	三菱制药株式会社	二氢吡唑并吡啶化合物及其制药用途
US7037902B2 (en)	2002-07-03	2006-05-02	Receptron, Inc.	Affinity small molecules for the EPO receptor
CA2528938A1 (en)	2003-06-13	2005-02-24	Zentaris Gmbh	Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
PL1746097T3 (pl) *	2005-07-20	2010-06-30	Aventis Pharma Sa	Skondensowane heterocykle 1,4-dihydropirydynowe, sposób ich wytwarzania, zastosowanie i zawierające je kompozycje
FR2945535B1 (fr)	2009-05-18	2011-06-10	Sanofi Aventis	Compose anticancereux et composition pharmaceutique le contenant

2009
- 2009-05-18 FR FR0902392A patent/FR2945535B1/fr not_active Expired - Fee Related
2010
- 2010-05-16 JO JO2010163A patent/JO2852B1/en active
- 2010-05-17 DK DK10728768.2T patent/DK2432766T3/da active
- 2010-05-17 TW TW099115713A patent/TWI441822B/zh not_active IP Right Cessation
- 2010-05-17 KR KR1020117030136A patent/KR20120032483A/ko not_active Withdrawn
- 2010-05-17 US US13/320,965 patent/US9073917B2/en not_active Expired - Fee Related
- 2010-05-17 PT PT107287682T patent/PT2432766E/pt unknown
- 2010-05-17 AU AU2010251013A patent/AU2010251013B2/en not_active Ceased
- 2010-05-17 CN CN201080032327.7A patent/CN102459193B/zh not_active Expired - Fee Related
- 2010-05-17 SG SG2011085529A patent/SG176169A1/en unknown
- 2010-05-17 PL PL10728768T patent/PL2432766T3/pl unknown
- 2010-05-17 BR BRPI1012201A patent/BRPI1012201A2/pt not_active IP Right Cessation
- 2010-05-17 MX MX2011012356A patent/MX2011012356A/es active IP Right Grant
- 2010-05-17 ME MEP-2013-121A patent/ME01542B/me unknown
- 2010-05-17 WO PCT/FR2010/050948 patent/WO2010133794A1/fr not_active Ceased
- 2010-05-17 AR ARP100101705A patent/AR076686A1/es unknown
- 2010-05-17 ES ES10728768T patent/ES2430989T3/es active Active
- 2010-05-17 EA EA201171429A patent/EA021084B1/ru not_active IP Right Cessation
- 2010-05-17 JP JP2012511323A patent/JP5656981B2/ja not_active Expired - Fee Related
- 2010-05-17 NZ NZ596464A patent/NZ596464A/en not_active IP Right Cessation
- 2010-05-17 CA CA2762233A patent/CA2762233C/fr not_active Expired - Fee Related
- 2010-05-17 RS RS20130444A patent/RS53002B/sr unknown
- 2010-05-17 MY MYPI2011005531 patent/MY152995A/en unknown
- 2010-05-17 SI SI201030384T patent/SI2432766T1/sl unknown
- 2010-05-17 EP EP10728768.2A patent/EP2432766B1/fr active Active
- 2010-05-17 MA MA34441A patent/MA33356B1/fr unknown
- 2010-05-17 HR HRP20130959AT patent/HRP20130959T1/hr unknown
- 2010-05-18 UY UY0001032644A patent/UY32644A/es not_active Application Discontinuation
2011
- 2011-11-14 IL IL216361A patent/IL216361A0/en unknown
- 2011-11-17 ZA ZA2011/08447A patent/ZA201108447B/en unknown
- 2011-11-18 CO CO11157425A patent/CO6400138A2/es active IP Right Grant
- 2011-11-18 CL CL2011002930A patent/CL2011002930A1/es unknown
2013
- 2013-10-17 CY CY20131100920T patent/CY1114850T1/el unknown
2014
- 2014-01-16 SM SM201400005T patent/SMT201400005B/xx unknown
2015
- 2015-06-02 US US14/728,846 patent/US9221817B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN102459193A (zh)	2012-05-16
EA201171429A1 (ru)	2012-05-30
EP2432766A1 (fr)	2012-03-28
AU2010251013B2 (en)	2015-08-20
ES2430989T3 (es)	2013-11-22
US9073917B2 (en)	2015-07-07
CL2011002930A1 (es)	2012-06-29
IL216361A0 (en)	2012-01-31
MA33356B1 (fr)	2012-06-01
FR2945535B1 (fr)	2011-06-10
TWI441822B (zh)	2014-06-21
WO2010133794A1 (fr)	2010-11-25
EP2432766B1 (fr)	2013-07-17
JP2012527436A (ja)	2012-11-08
CY1114850T1 (el)	2016-12-14
EA021084B1 (ru)	2015-04-30
HRP20130959T1 (hr)	2013-11-22
DK2432766T3 (da)	2013-10-28
FR2945535A1 (fr)	2010-11-19
US9221817B2 (en)	2015-12-29
MX2011012356A (es)	2011-12-14
CO6400138A2 (es)	2012-03-15
US20120220621A1 (en)	2012-08-30
ZA201108447B (en)	2013-01-30
AU2010251013A1 (en)	2011-12-08
SI2432766T1 (sl)	2013-11-29
TW201100418A (en)	2011-01-01
SMT201400005B (it)	2014-03-07
CN102459193B (zh)	2014-08-27
MY152995A (en)	2014-12-31
AR076686A1 (es)	2011-06-29
US20150266877A1 (en)	2015-09-24
ME01542B (me)	2014-04-20
UY32644A (es)	2010-12-31
BRPI1012201A2 (pt)	2016-04-05
KR20120032483A (ko)	2012-04-05
HK1167388A1 (en)	2012-11-30
PL2432766T3 (pl)	2013-12-31
RS53002B (sr)	2014-04-30
NZ596464A (en)	2014-01-31
CA2762233C (fr)	2017-11-28
CA2762233A1 (fr)	2010-11-25
SG176169A1 (en)	2011-12-29
JO2852B1 (en)	2015-03-15
JP5656981B2 (ja)	2015-01-21

Publication	Publication Date	Title
PT2432766E (pt)	2013-10-23	Composto anti-canceroso e composição farmacêutica que o contém
UA94052C2 (uk)	2011-04-11	Похідні піридазину
SG148178A1 (en)	2008-12-31	Indozolone derivatives as 11b-hsd1 inhibitors
TW200608972A (en)	2006-03-16	Aryl-pyridine derivatives
MX2011012627A (es)	2011-12-14	Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
GB0114286D0 (en)	2001-08-01	Nucleoside Derivatives
MX2010006799A (es)	2010-10-05	Benzofuropirimidinonas como inhibidores de la proteina cinasa.
IN2012DN03337A (pt)	2015-10-23
EA018193B3 (ru)	2014-07-30	Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MX2010005824A (es)	2010-06-11	Derivados de aminotiazol.
TW200621737A (en)	2006-07-01	2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2008143240A1 (ja)	2008-11-27	特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
MX2008016426A (es)	2009-01-19	Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
MY143568A (en)	2011-05-31	11b-hsd1 inhibitors for the treatment of diabetes
DE602006021539D1 (en)	2011-06-09	Morpholine als 5ht2c-agonisten
MX2012007225A (es)	2012-07-30	Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
TW200630364A (en)	2006-09-01	2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MY139522A (en)	2009-10-30	New alkyl-pyridines as 11-beta inhibitors for diabetes
MX2009003169A (es)	2009-04-03	Derivados de sulfonamida.
TW200740764A (en)	2007-11-01	Pyrazolone derivatives
MX2009004295A (es)	2009-05-05	Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
IL191670A0 (en)	2008-12-29	Compounds for the inhibition of apoptosis
TNSN08242A1 (en)	2009-10-30	2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
TH135249A (th)	2014-07-21	สารประกอบตัวยับยั้งออโรราต้านมะเร็งและองค์ประกอบทางเภสัชกรรมที่มีสารดังกล่าว, กระบวนการและอินเทอร์มิเดียทสำหรับการเตรียมสารเหล่านั้น
MX2009013240A (es)	2010-01-25	Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones.